Medical/Pharmaceuticals
BioShin Expands Senior Leadership Team: Sarah Lu Joins BioShin as Chief Medical Officer, Mary Ma Joins BioShin as Chief Commercial Officer
SHANGHAI, July 8, 2021 /PRNewswire/ -- BioShin Limited today announced the appointment of Dr.Zhihong (Sarah) Lu as Chief Medical Officer and Dr. Ma (Mary) Li as Chief Commercial Officer. Sarah will play a critical role in BioShin's clinical development of pipeline products inAsia-Pacific markets,...
2021-07-08 12:01
2146
Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis
* Both batoclimab 340 mg and 680 mg treatment groups demonstrated rapid, substantial and persistent clinical improvement over placebo * Favorable safety and tolerability profile with no serious adverse events (SAEs) and no adverse events (AEs) leading to discontinuation * Strong IgG reductio...
2021-07-06 21:06
17933
Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD
ADELAIDE, Australia, July 6, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics or Company), a global, clinical stage biopharmaceutical company, is pleased to announce that it has initiated a Phase2b trial (the ATTUNE Study) to evaluate the tablet formulation of BNC210 in p...
2021-07-06 18:00
16951
Arctic Vision Joins Forces with the University of Hong Kong Department of Ophthalmology to Discover and Develop Novel Neuroprotective Therapies for Ocular Disease
SHANGHAI and HONG KONG, July 4, 2021 /PRNewswire/ -- Arctic Vision, a China -based clinical-stage ophthalmology company focuses on developing innovative therapies for pan-ocular diseases, announcing today a new research collaboration with Prof.Christopher Leung, Head and Clinical Professor at the ...
2021-07-05 08:00
1433
Transcenta Provides Program Update for Anti-Claudin18.2 Monoclonal Antibody TST001 and Reports Promising Early Anti-Tumor Responses in Patients with Gastric Cancer
SUZHOU, China, July 2, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announces that promising anti-tumor response...
2021-07-02 21:02
2727
First Naturally-designed and Personalised Bioprosthesis SingValve Set to Revolutionise Heart Valve Surgery
SINGAPORE, July 1, 2021 /PRNewswire/ -- A naturally-designed human-like personalised heart valve bioprosthesis developed by a team of clinician-scientists from theNational University Health System (NUHS) looks set to be a game changer in the next generation of "personalised medicine" and further...
2021-07-01 21:00
2560
Korea National Institute of Health (KNIH) conducts field inspection of companies with mRNA technology
SEOUL, South Korea, July 1, 2021 /PRNewswire/ -- Korea National Institute of
Health (KNIH), Korea's top research center in the field of hygiene and medicine
(with Mr. Kwon Jun-Wook as President) conducted a field inspection of key
companies with mRNA technology.
2021-07-01 21:00
1816
I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio
* First patient dosed in U.S. phase 1 clinical trial of TJ-CD4B/ABL111 in patients with advanced or metastatic solid tumors * China sites to join the dose expansion part of the study to accelerate TJ- CD4B/ABL111 development * Results of TJ-L14B/ABL503 preclinical studies accepted for publica...
2021-07-01 20:00
13173
Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's
MELBOURNE, Australia and SAN FRANCISCO, July 1, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the granting of a new composition of matter patent by the United States Patent and Trademark Office (USPTO). The patent secures a ...
2021-07-01 19:50
13160
Joint Commission International publishes fourth edition of International Accreditation Standards for Laboratories
Standards and policies in latest edition become effective 1 January 2022 OAK BROOK, Ill., July 1, 2021 /PRNewswire/ -- Joint Commission International (JCI) today publishedJoint Commission International Accreditation Standards for Laboratories, Fourth Edition. The manual provides requirements for ...
2021-07-01 08:00
1191
Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs
SYDNEY, June 30, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801. Key Points * GBM AGILE pivotal study of paxalisib is...
2021-06-30 22:00
30196
VUNO Inks Deal with Samsung Electronics to Embed AI-powered Algorithms in Samsung's Premium Mobile X-ray System
SEOUL, South Korea, June 30, 2021 /PRNewswire/ -- South Korean artificial intelligence (AI) developer, VUNO Inc., announced today a partnership with Samsung Electronics Co., Ltd., global medical device company to incorporate its AI-powered chest X-ray diagnostic solution, VUNO Med®-Chest X-ray™, ...
2021-06-30 21:00
1373
I-Mab Honored with Top Rankings by Institutional Investor
SHANGHAI and GAITHERSBURG, Md., June 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it was ranked among the top companies by leading gl...
2021-06-30 20:00
12565
Akeso Awarded as 2021 "Most Honored Company" by Institutional Investor
HONG KONG, June 30, 2021 /PRNewswire/ -- Akeso, Inc. ("Akeso" or the "Company", stock code: 9926.HK) is pleased to announce today that, Akesohas been awarded as "Most Honored Company" in the "2021 All-Asia Executive Team" survey published byInstitutional Investor, and has been ranked top 3 in all...
2021-06-30 16:00
13219
OnCusp Therapeutics Commences Operations to Advance Innovative Oncology Therapies
NEW YORK, June 29, 2021 /PRNewswire/ -- OnCusp Therapeutics (or "OnCusp"), a global biopharmaceutical company focused on translating cutting-edge research assets into innovative oncology therapeutics, announced that it has officially commenced operations both inNew York and Shanghai. OnCusp succ...
2021-06-30 09:29
1407
Cynosure Celebrates 30 Years of Innovation
Aesthetics leader recognizes milestone with focus on future skin aesthetics innovation to help reveal the Beautiful Energy within everyone WESTFORD, Mass., June 29, 2021 /PRNewswire/ -- Since 1991, Cynosure has been a leader in the beauty aesthetics space, creating a comprehensive range of exper...
2021-06-29 21:00
1562
Hanmi Pharmaceutical finds new innovative potential for "Efpeglenatide"
SEOUL, South Korea, June 29, 2021 /PRNewswire/ -- Hanmi Pharmaceutical (hereinafter Hanmi) recently announced that its new, long-acting diabetes biologic drug, efpeglenatide, was shown to significantly reduce incidences of major adverse cardiovascular events (MACE) and kidney disease in the resul...
2021-06-29 21:00
1827
I-Mab Announces Upcoming Participation at July Conference
SHANGHAI and GAITHERSBURG, Md., June 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conference in July. D...
2021-06-29 20:00
8267
Lianhua Qingwen Granted Market Access as Medicine in Ukraine: Yiling Pharmaceutical
SHIJIAZHUANG, China, June 29, 2021 /PRNewswire/ -- Yiling Pharmaceutical disclosed in a statement on Monday that it had received the medicine registration document for Lianhua Qingwen Capsules from the Ministry of Health ofUkraine. As the leading product of Yiling Pharmaceutical, Lianhua Qingwen...
2021-06-29 16:41
2485
First in China! Neurophth announced the first patient has been dosed in G.O.L.D. clinical trial for the gene therapy treatment of LHON
* Novel and one-time intravitreal injection of ND4 gene therapy for the treatment of LHON potentially restored vision * Phase I/II/III clinical trial expected to enroll patients with LHON due to ND4 mutation WUHAN, China and SAN DIEGO, June 28, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd...
2021-06-28 21:33
1588
Week's Top Stories
Most Reposted
Thailand Tops 2024 Consumer Review Awards by Agoda
[Picked up by 329 media titles]
2024-09-26 11:00
WARHAMMER 40,000: SPACE MARINE VR - DEFENDERS OF AVARAX NOW AVAILABLE AT ZERO LATENCY VR VENUES WORLDWIDE
[Picked up by 314 media titles]
2024-09-26 00:00
Advantech Unveils Expanded Singapore Office to Boost ASEAN Presence and Support AIoT Innovations with Strategic Partnerships
[Picked up by 312 media titles]
2024-09-23 13:37
Circles Partners with Telkomsel, Providing an Advanced Software-as-a-Service (SaaS) Platform to Enhance Customer Digital Experience
[Picked up by 297 media titles]
2024-09-27 10:00RuggON Debuts at the Largest Mining Expo, MINExpo 2024 Showcasing Rugged Solutions for the Trillion-Dollar Mining Market
[Picked up by 294 media titles]
2024-09-23 22:00
Most Read
RuggON Debuts at the Largest Mining Expo, MINExpo 2024 Showcasing Rugged Solutions for the Trillion-Dollar Mining Market
2024-09-23 22:00
6930
WARHAMMER 40,000: SPACE MARINE VR - DEFENDERS OF AVARAX NOW AVAILABLE AT ZERO LATENCY VR VENUES WORLDWIDE
2024-09-26 00:00
6443
Advantech Unveils Expanded Singapore Office to Boost ASEAN Presence and Support AIoT Innovations with Strategic Partnerships
2024-09-23 13:37
6314
Sobot Reflects on its Partnership with Lilith Games on Lilith's 11th Anniversary
2024-09-24 10:00
5537
Thailand Tops 2024 Consumer Review Awards by Agoda
2024-09-26 11:00
5257